期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替唑咪的两大误区 被引量：1

下载PDF
导出
摘要 近年来，多发性骨髓瘤（MM）的疗效取得了明显的进步。早在上个世纪80代年，MM患者中位生存期在2年左右，
作者 齐军元
机构地区 中国医学科学院血液病医院(血液学研究所)
出处 《中国处方药》 2013年第3期29-32,共4页 Journal of China Prescription Drug
关键词 硼替唑咪 多发性骨髓瘤 中位生存期
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Richardson PG,Xie W, Mitsiades C,et al.Single- -agent bortezomib in previously untreated multiple mye- loma:efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol,2009,27(21):3518-3525.
  • 2Mujtaba T, Dou QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib.Discov Med,2011,12(67):471-480.
  • 3Ciechanover A.Proteolysis:from the lysosome to ubiquitin and the proteasome.Nat Rev Mol Cell Biol,2005,6(1):79-87.
  • 4Richardson PG,Sonneveld ESchuster MW, et al.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.N Engl J Med,2005,352(24):2487-2498.
  • 5San Miguel JF, Schlag R,Khuageva NK,et al.Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.N Engl J Meal, 2008,359(9):906-917.
  • 6Dimopoulos MA,Mateos MV, Richardson PG,et al.Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan- prednisone in newly diagnosed patients with multiple myeloma:subanalysis of the phase 3 VISTA study.Eur J Haematol, 2011,86(1):23-31.
  • 7Richardson PG,Briemberg H,Jagannath S,et al.Frequency, characteristics, and reversibifity of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.J Clin Oncol, 2006,24(19):3113- 3120.
  • 8Dispenzieri A,Kyle RA.Neurological aspects of multiple myeloma and related disorders.Best Pract Res Clin Haematol,2005,18(4):673-688.
  • 9Bringhen S,Lamcca A,Rossi D,et al.Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.Blood,2010,116(23):4745 -4753.
  • 10Cavo M,Taeehetti EPatriarca F,et al.Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before,and consolidation therapy after,double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet,2010,376(9758):2075 -2085.

同被引文献9

  • 1Terpos E, Roussou M, Dimopoulos MA. Bortezomib in multiple my-eloma [ J ]. Expert Opin Drug Metal Toxicol, 2008,4 ( 5 ) : 639 - 654.
  • 2Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated hy high dose therapy and hemopoietic stem cell transplantation. My- eloma Subcommittee of the EMBT. European Group for Blood and Marrow Transplant [ J ]. Br J Haematol, 1998,102 ( 5 ) : 1115 - 1123.
  • 3Durie BG, Harousseau JL, Miguel JS, et al. International uniform re- sponse criteria form multiple myeloma [ J ]. Leukemia, 2006, 20 (9) :1467 - 1473.
  • 4Richardson PG, Barlogie B, Berensnn J, et al. A phase 2 study ot hortezomib in relapsed, refactory myeloma [ J ]. N Engl J Med,2003,348(26) :2609 -2617.
  • 5Jakubowiak A J, Griffith KA, Rcece DE, et al. Lenalidomide, Imrt- ezomih, pegylated liposumal doxorubiein, and dexamethasone in newly diagnosed multiple myeloma:a phase 1/2 Multiple Myeloma Research Consortimn trial[ J]. Blood ,2011,118 (3) :535 - 543.
  • 6Mateos MV, San Miguel JF. Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous for- mulation in muhiple myeloma [ J ]. Ther Adv Hematol, 2012,3 (2) :117 - 124.
  • 7赵冰冰,王焰,糜坚青,沈志祥,陈瑜,陈秋生,徐岚,吕银祥.硼替佐米为主的化疗方案对改善初治多发性骨髓瘤患者生存的作用[J].上海交通大学学报（医学版）,2011,31(12):1793-1796. 被引量：12
  • 8张芙蓉,杨林花,张睿娟,葛晓燕,张建华,康建民.不同化疗方案治疗多发性骨髓瘤的临床疗效观察[J].临床血液学杂志,2013,26(6):773-775. 被引量：1
  • 9岑海燕,施文瑜,徐梦麒,黄红铭.硼替佐米为主的联合方案治疗多发性骨髓瘤的临床观察[J].临床血液学杂志,2014,27(1):61-63. 被引量：13

引证文献1

二级引证文献16

中国处方药
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部